目的 评价注射用还原型谷胱甘肽联合盐酸二甲双胍缓释片治疗糖尿病神经病变的临床疗效。方法 选取2017年1月-2018年1月西电集团医院收治的92例糖尿病神经病变患者作为研究对象，将患者按随机数字表法分为对照组和治疗组，每组各46例。对照组患者口服盐酸二甲双胍缓释片，3片/d。治疗组在对照组治疗的基础上静脉滴注注射用还原型谷胱甘肽，1.8 g加入到0.9%氯化钠注射液250 mL中，1次/d。两组患者均连续治疗1个月。观察两组患者的临床疗效，同时比较两组的相关指标、运动神经传导速度（MNCV）、感觉神经传导速度（SNCV）、血清游离脂肪酸（FFA）、肿瘤坏死因子-α（TNF-α）和白介素-6（IL-6）水平。结果 治疗后，治疗组总有效率为95.65%，明显高于对照组的82.61%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者空腹血糖（FBG）、糖化血红蛋白（HbA1c）和三酰甘油（TG）水平均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组FBG、HbA1c和TG水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的正中神经、腓神经的MNCV和SNCV均明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组正中神经、腓神经的MNCV和SNCV明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组患者的FFA、TNF-α、IL-6水平均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组FFA、TNF-α、IL-6水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 注射用还原型谷胱甘肽联合盐酸二甲双胍缓释片治疗糖尿病神经病变具有较好的临床疗效，可明显改善患者的临床症状，降低血糖水平，提高神经传导速度，减少炎性因子，安全性好，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Reduced Glutathione for injection combined with Metformin Hydrochloride Sustained-release Tablets in treatment of diabetic peripheral neuropathy. Methods Patients (92 cases) with diabetic peripheral neuropathy in Xi'an XD Group Hospital from January 2017 to January 2018 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Metformin Hydrochloride Sustained-release Tablets, 3 tablets/d. Patients in the treatment group were iv administered with Reduced Glutathione for injection on the basis of the control group, 1.8 g added into 0.9% sodium chloride injection 250 mL, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the relevant indicators, MNCV, SNCV, FFA, TNF-α, and IL-6 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment groups was 95.65%, which was higher than 82.61% in the control group, and there were differences between two groups (P<0.05). After treatment, the FBG, HbA1c, and TG levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the FBG, HbA1c, and TG levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the MNCV and SNCV of the median nerve and common peroneal nervous in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the MNCV and SNCV in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the FFA, TNF-α, and IL-6 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of FFA, TNF-α, and IL-6 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Reduced Glutathione for injection combined with Metformin Hydrochloride Sustained-release Tablets has significant clinical effect in treatment of diabetic peripheral neuropathy, can significantly improve the clinical symptoms of patients, reduce blood glucose level, improve nerve conduction speed, reduce inflammatory factors, with good safety, which has a certain clinical application value.